OncoMatch/Clinical Trials/NCT06709885
HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer
Is NCT06709885 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Chidamide + Tislelizumab + chemotherapy (CapeOX ) and CapeOX for colon adenocarcinoma.
Treatment: Chidamide + Tislelizumab + chemotherapy (CapeOX ) · CapeOX — The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer. The main questions it aims to answer are: Can HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of HDAC inhibitors and neoadjuvant immunochemotherapy achieve a better long-term prognosis than neoadjuvant therapy?
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR proficient
dMMR/MSI-H [excluded]
Required: MSI microsatellite stable
dMMR/MSI-H [excluded]
Disease stage
Required: Stage HIGH-RISK T3 (TNM)
assessed by abdominal contrast-enhanced CT/abdominopelvic MRI as high-risk T3 (tumor destroys muscle wall and extends to pericolonic fat, protruding more than 5 mm into adjacent mesenteric fat) or T4 (tumor penetrates the visceral peritoneal surface or directly invades or adheres to adjacent organs or structures).
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Have not received any anti-tumor therapy for cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: chemotherapy
Have not received any anti-tumor therapy for cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: surgery
Have not received any anti-tumor therapy for cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: immunotherapy
Received any treatment against the mechanism of action of tumor immunity, such as immunization, HDACi, etc.
Cannot have received: HDAC inhibitor
Received any treatment against the mechanism of action of tumor immunity, such as immunization, HDACi, etc.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify